Sage Therapeutics, Alzheimer's disease
Sage Therapeutics’ stock slides after biotech says it will cease development of Alzheimer’s treatment
Sage Therapeutics Inc.’s stock tumbled 12.8% early Tuesday, after the company said a mid-stage trial of a treatment for mild cognitive impairment and mild dementia in Alzheimer’s disease failed to meet its main goal.
Sage Therapeutics Phase 2 LIGHTWAVE Study In Alzheimer's Disease Fails; Stock Down In Pre-Market
(RTTNews) - Sage Therapeutics, Inc. (SAGE) Tuesday said its Phase 2 LIGHTWAVE study to evaluate dalzanemdor in participants with mild cognitive impairment (MCI) or mild dementia due to Alzheimer's Disease (AD) failed to meet the primary goal. The company's shares were down more than 12 percent in pre-market.
Sage Therapeutics Stock Plunges on Disappointing Study Results for Alzheimer’s Treatment
The biopharmaceutical company isn’t planning further clinical development of dalzanemdor to treat Alzheimer’s.
Sage Therapeutics Ends Development of Dalzanemdor in Alzheimer's Disease
Sage Therapeutics does not plan further clinical development of its dalzanemdor drug candidate in Alzheimer's disease following its failure in a mid-stage study.
Sage Therapeutics to discontinue development of Alzheimer’s drug
Sage Therapeutics said on Tuesday it will discontinue the development of its Alzheimer's disease drug as it did not meet the main goal in a mid-stage trial.
Sage Therapeutics stock drops after disappointing Alzheimer's trial results
Sage Therapeutics shares fell as much as 25% in premarket trading after the company announced disappointing topline results from its Phase 2 LIGHTWAVE study of dalzanemdor (SAGE-718) for the treatment of mild cognitive
Sage Therapeutics Stock Down Almost 40% in 3 Months: Here's Why
Sage Therapeutics, Inc. SAGE is focused on developing life-changing brain health medicines. In July, Sage Therapeutics and partner Biogen BIIB announced top-line data from the phase II KINETIC 2 study,
Hosted on MSN1d
Alzheimer's disease could be stopped in its tracks by new drug with potential to 'prevent progression'
This drug has the potential to be more targeted than others currently being studied, and we hope it will result in fewer ...
HealthDay on MSN12h
Scientists Discover the Brain's Waste-Disposal System, With Clues to Alzheimer's Disease
The brain has a waste-disposal system that clears away junk proteins that contribute to the development of dementia and ...
Worcester Telegram on MSN1d
Frontotemporal dementia: Not as well known as Alzheimer's disease but still deadly
Frontotemporal dementia can be hard to diagnose because while dementia can be part of the illness, it's not a factor in all ...
Afro12d
Neurologist speaks on fighting Alzheimer’s Disease with diet and exercise
Discover how exercise, a healthy diet, and socialization can help combat Alzheimer's disease. Learn more about the importance ...
Longview walks to help end Alzheimer’s disease
Longview residents were out in front of the Gregg County Courthouse on Saturday to take part in the Walk to End Alzheimer’s ...
Science Daily1d
Clinical trial shows synthetic cannabis reduces agitation in Alzheimer's disease
Researchers show that a pill form of the drug dronabinol, an FDA-approved synthetic version of marijuana's main ingredient, THC, reduces agitation in patients with Alzheimer's by an average of 30%.
McKnight's Long-Term Care News3d
Promising new Alzheimer’s drug candidate developed by international research team
A team of international researchers has found a promising new drug candidate for the treatment of Alzheimer’s disease. The scientists say they have developed a peptide inhibitor called RI-AG03 ...
Key mechanisms in asymptomatic Alzheimer's disease brains offer potential protection against cognitive decline
Researchers at Indiana University School of Medicine are examining the brains of individuals with asymptomatic Alzheimer's ...
Milwaukee Independent8d
New blood tests could help doctors diagnose Alzheimer’s disease faster and more accurately
New blood tests could help doctors diagnose Alzheimer’s disease faster and more accurately, researchers reported in July. But ...
Alzheimer’s Game Changer: Dual-Action Drug Attacks Disease at Its Core
AG03, targets two key areas of the Tau protein in Alzheimer's disease, showing effectiveness in lab and fruit fly models.
All the News That’s Fit: Alzheimer’s drug study, rice balls record and Hawking’s words
Muscae volitantes — “eye floaters” are those little, transparent threads that you see floating across your eyeball. Generally ...